Combination Treatments of Plasma Exchange and Umbilical Cord-Derived Mesenchymal Stem Cell Transplantation for Patients with Hepatitis B Virus-Related Acute-on-Chronic Liver Failure: A Clinical Trial in China

Table 2

Unfavorable outcome and survival rate.

Parameters	Control	UC-MSC	PE	PE + UC-MSC	All
	()	()	()	()	()
Unfavorable outcome
30 days	12 (40.00)	5 (16.67)	7 (23.33)	2 (10.00)	26 (23.64)	0.063
60 days	16 (53.33)	16 (53.33)	12 (40.00)	5 (25.00)	49 (44.55)	0.145
90 days	16 (53.33)	18 (60.00)	16 (53.33)	7 (35.00)	57 (51.82)	0.368
180 days	18 (60.00)	19 (63.33)	17 (56.67)	9 (45.00)	63 (57.27)	0.622
360 days	18 (60.00)	19 (63.33)	18 (60.00)	10 (50.00)	65 (59.09)	0.821
Survival rate
30 days	19 (63.33)	26 (86.67)	24 (80.00)	18 (90.00)	87 (79.09)	0.079
60 days	15 (50.00)	16 (53.33)	20 (66.67)	15 (75.00)	66 (60.00)	0.228
90 days	15 (50.00)	15 (50.00)	17 (56.67)	13 (65.00)	60 (54.55)	0.693
180 days	13 (43.33)	14 (46.67)	17 (56.67)	11 (55.00)	55 (50.00)	0.705
360 days	13 (43.33)	14 (46.67)	16 (53.33)	10 (50.00)	53 (48.18)	0.883

UC-MSC, umbilical cord-derived mesenchymal stem cells; PE, plasma exchange.